Enhertu (Trastuzumab Deruxtecan)

Trastuzumab deruxtecan is a cancer medicine used for breast cancer and some other cancers that have a protein called HER2. It works like a guided missile: an antibody finds the cancer cells and delivers a chemotherapy drug right into them. It's given as an infusion into a vein.

Brand names:Enhertu
Medication

What people taking Enhertu (Trastuzumab Deruxtecan) report

Every report comes from a Lived member, sent anonymously.

Have you tried Enhertu (Trastuzumab Deruxtecan) for Breast Cancer?

NameHow it went

About Enhertu (Trastuzumab Deruxtecan)

What It's For

Trastuzumab deruxtecan, sold as Enhertu, is an intravenous cancer medicine for adults whose tumors carry HER2, a protein on the surface of some cancer cells that helps them grow. Whether it fits depends on a lab test of the tumor. Pathologists score HER2 from 0 to 3+, and the medicine is approved for cancers at several of those levels. Its largest use is breast cancer. In HER2-positive breast cancer (a score of 3+, or extra copies of the HER2 gene), it can be given before surgery for stage II or III disease, after surgery when cancer remains despite earlier HER2 treatment, as a first treatment for metastatic cancer together with pertuzumab (Perjeta), or later, after other HER2 treatments have stopped working. It is also approved for metastatic breast cancer with lower HER2 levels, called HER2-low or HER2-ultralow. For hormone receptor-positive cancer at these levels, it is used once hormone therapy has stopped controlling it. For HER2-low cancer, it can also follow chemotherapy. Beyond breast cancer, it treats HER2-positive stomach cancer and cancer where the stomach meets the esophagus after a trastuzumab-based treatment, advanced non-small cell lung cancer with a HER2 gene mutation after earlier treatment, and advanced HER2-positive (3+) solid tumors of other types when no satisfactory option remains. The lung and other solid tumor approvals are accelerated approvals: they rest on how often and how long tumors shrank, and keeping them may depend on confirmatory studies showing a clinical benefit. Enhertu is a different medicine from Herceptin (trastuzumab) and Kadcyla (ado-trastuzumab emtansine), two other HER2 treatments with similar names, and they are never substituted for one another.

How It Works

Enhertu is an antibody-drug conjugate: an antibody joined to a chemotherapy drug. The antibody part is a version of trastuzumab that locks onto HER2 on cancer cells. Once attached, the cell pulls the whole medicine inside, where enzymes cut the link and release the chemotherapy, called deruxtecan. Deruxtecan blocks topoisomerase I, an enzyme a cell needs to copy its DNA. Without it, DNA damage builds up and the cell dies. Delivering chemotherapy this way concentrates it in HER2-bearing cells, though it still reaches the rest of the body and causes chemotherapy-type side effects.

Dosage & Administration

Enhertu is given as an infusion into a vein at a cancer center, usually once every 3 weeks. The dose is calculated from body weight. Stomach and esophageal cancer use a somewhat higher dose than the other cancers. The first infusion takes about 90 minutes; later infusions can take about 30 minutes if the earlier ones went smoothly. How long treatment lasts depends on the setting. Before surgery for early breast cancer, it is given for 4 cycles and followed by other HER2 treatment with chemotherapy. After surgery, the course is 14 cycles. For advanced cancer, it continues for as long as it controls the cancer and side effects stay manageable. Because it commonly causes nausea, including nausea that starts a day or more later, anti-nausea medicine is given before each infusion. Blood counts are checked before each dose. Side effects are managed by delaying a dose or lowering it, and once lowered, the dose is not raised again. A missed dose is given as soon as possible rather than waiting for the next planned date.

Side Effects

Nausea is the most common side effect, affecting about 7 in 10 people, along with tiredness, vomiting, constipation, diarrhea, poor appetite, muscle or bone aches and hair thinning or loss. Blood tests often show low white cells, red cells or platelets and raised liver enzymes, which the care team tracks rather than something a person feels. The most serious risk is inflammation and scarring of the lungs, called interstitial lung disease (ILD) or pneumonitis. It affected about 12% of people in studies and was sometimes fatal, and it usually appeared months into treatment rather than right away. A new or worsening cough, shortness of breath, fever or any other new breathing problem should be reported to the care team immediately, even if it seems minor, because catching it early changes treatment. Low white cell counts raise the risk of infection. A fever, especially with other signs of infection, also calls for an immediate call to the care team. The medicine can weaken the heart's pumping, so new or worsening breathlessness, swelling in the ankles or legs, a racing or pounding heartbeat, sudden weight gain, dizziness or fainting should be reported right away.

Interactions & Warnings

Enhertu can seriously harm a developing baby. Pregnancy is checked before treatment starts. Women who could become pregnant need effective contraception during treatment and for 7 months after the last dose, and men with partners who could become pregnant need it for 4 months after. Anyone who becomes pregnant or thinks they might be should tell the care team promptly. Breastfeeding is not advised during treatment or for 7 months afterward. The medicine may also reduce male fertility, which is worth raising before starting if future children matter. The prescribing information lists no specific drug interactions, but the care team should still know every medicine and supplement being taken. People with moderate kidney impairment had more mild lung inflammation in studies and are watched more closely, and the right dose for severe kidney disease has not been established. The medicine has not been studied in people with significant heart disease or already weak heart pumping, so existing heart problems need to be discussed beforehand.

What to Expect

Before treatment, the tumor is tested to confirm HER2 status (or a HER2 mutation for lung cancer), and the heart's pumping strength is measured, usually with an echocardiogram (a heart ultrasound). During treatment, each visit includes blood tests and a check for breathing symptoms, and heart scans and imaging are repeated at intervals. Many people need a delay or dose reduction at some point; this is a routine part of keeping treatment going rather than a sign it has failed. In advanced breast cancer, the benefit in studies was meaningful time rather than cure. For HER2-low cancer after chemotherapy, people lived a median of about 23 months, compared with about 17 months on standard chemotherapy. In early HER2-positive breast cancer treated before surgery, about two thirds had no invasive cancer left at surgery, a higher share than with the standard chemotherapy it was compared with. Response varies widely from person to person, and repeat scans show whether it is working. Because lung inflammation can appear late, watchfulness for breathing symptoms matters for the whole course, not just the first few infusions.

Questions to Ask Your Doctor

  1. 1.What did my tumor's HER2 test show, and why does that make Enhertu a good option compared with other treatments?
  2. 2.What results should we realistically hope for, and how will we know whether it is working?
  3. 3.How will you monitor my lungs and heart, and who should I call at any hour if I develop a cough, fever or shortness of breath?
  4. 4.How will we manage nausea and fatigue, and what happens if I need a dose delay or reduction?
  5. 5.What contraception and fertility planning should I consider before starting?

Last reviewed • Oct 2026

Educational content, not medical advice.